Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
Universitat de Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Universitat de Barcelona (2)
2022
2021
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394